强化降压与深部脑出血血肿扩大风险的关联
本研究为ATACH-2试验的事后探索性分析,纳入870例深部脑出血患者中780例有完整影像数据者。强化降压(收缩压目标110-139 mm Hg)较标准治疗(140-179 mm Hg)与血肿扩大风险降低相关(OR 0.61),该关联 mainly 见于基底节出血而非丘脑出血,但未改善90天改良Rankin量表评分分布。
要点
- 强化降压与深部脑出血血肿扩大风险降低相关,尤其基底节出血。
- 丘脑出血未见强化降压降低血肿扩大风险。
- 强化降压未改善90天改良Rankin量表评分分布。
核心结论
- 强化降压治疗与深部脑出血血肿扩大风险降低相关, specifically 在基底节出血中。
研究设计与样本
- ATACH-2国际多中心随机临床试验的探索性分析,2011年5月至2015年9月纳入原发性ICH患者并随访90天。
- 1000例试验参与者中870例(87.0%)为深部ICH,其中780例(89.7%)有完整神经影像数据(336例丘脑出血和444例基底节出血)。
主要发现
- 强化治疗与90天改良Rankin量表评分分布改善无关。
关键数值与推荐
- 血肿扩大定义为基线至24小时血肿体积增加大于33%。
- 强化治疗收缩压目标为110-139 mm Hg,标准治疗目标为140-179 mm Hg。
临床怎么用
- 对于基底节区深部脑出血患者,急性期强化降压可能有助于降低血肿扩大风险。
- 丘脑出血患者强化降压对血肿扩大的获益不明显,需个体化决策。
- 强化降压未显示改善90天功能结局,临床决策需权衡获益与风险。
局限性
- 本研究为ATACH-2试验的探索性分析,非预设主要分析。
- 仅纳入有完整神经影像数据的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hypertension is the strongest risk factor for spontaneous intracerebral hemorrhage (ICH) involving deep brain regions, but it appears to be unknown if intensive blood pressure reduction in the acute care setting decreases hematoma expansion or improves outcomes in patients with deep ICH. OBJECTIVE: To determine whether intensive blood pressure reduction is associated with decreased risk of hematoma expansion and changes in 90-day modified Rankin Scale scores and if these associations are modified by the specific deep-brain nuclei involved. DESIGN, SETTING, AND PARTICIPANTS: This study is an exploratory analysis of the Antihypertensive Treatment of Acute Cerebral Hemorrhage-2 international, multicenter randomized clinical trial, which was conducted from May 2011 to September 2015, enrolled eligible patients with primary ICH, and followed up with them for 90 days. Patients who had ICH and complete neuroimaging data were included in the analysis. Data analysis was completed from July 2018 to December 2018. EXPOSURES: Participants were randomized to either intensive treatment (with a systolic blood pressure target of 110-139 mm Hg) or standard treatment (with a systolic blood pressure target of 140-179 mm Hg). MAIN OUTCOMES AND MEASURES: The main outcome was hematoma expansion, defined as an increase greater than 33% in hematoma volume between baseline and 24 hours. Functional outcome was evaluated 90 days after the ICH via the modified Rankin Scale. RESULTS: Of 1000 trial participants, 870 (87.0%) had deep ICH, of whom 780 (89.7%) had complete neuroimaging data (of 336 thalamic and 444 basal ganglia hemorrhages). The baseline characteristics of the intensive and standard treatment groups remained balanced in this subgroup of the original study. Intensive treatment was associated with a decreased risk of hematoma expansion in univariable analysis (odds ratio [OR], 0.62 [95% CI, 0.43-0.87]; P = .006) and multivariable analysis (OR, 0.61 [95% CI, 0.42-0.88]; P = .009). This association was modified by the specific deep location of the ICH (OR, 0.44 [95% CI, 0.22-0.96]; interaction P = .02), with stratified analyses showing a reduction in risk of hematoma expansion with intensive vs standard treatment among basal ganglia ICH (OR, 0.44 [95% CI, 0.27-0.72]; P = .001) but not thalamic ICH (OR, 0.91 [95% CI, 0.51-0.64]; P = .76). Intensive treatment was not associated with an improvement in the modified Rankin Scale score distribution. CONCLUSIONS AND RELEVANCE: Compared with standard treatment, intensive blood pressure treatment was associated with reduced hematoma expansion in deep ICH, specifically among basal ganglia hemorrhages.
引用
- Leasure AC, Qureshi AI, Murthy SB, et al. Association of Intensive Blood Pressure Reduction With Risk of Hematoma Expansion in Patients With Deep Intracerebral Hemorrhage. JAMA Neurol. 2019. PMID: 31081862. doi:10.1001/jamaneurol.2019.1141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。